$Esperion Therapeutics (ESPR.US)$As of February 13, 2025, the stock price of ESPR was $1.87, slightly down 0.53% from the previous trading day. Despite the negative fund flow, the stock price did not decline significantly, which may indicate that the market has a relatively positive outlook on the company.
Link for article here Real Rumors Daiichi Sankyo Europe Has Intentions To Acquire Esperion Therapeutics$Esperion Therapeutics (ESPR.US)$. . Daiichi Sankyo Europe (DSE) Poised to Acquire Esperion Therapeutics Amid Leaked Insider Information Recent rumors circulating on social media, supported by credible leaks from individuals connected to both DSE and E...
3
2
1
Report
老实和尚
:
Already bought. The days of the stock price being artificially suppressed are tough. Hopefully, this news will be confirmed soon, and then the stock price will no longer be held down. I believe the acquisition price this year will be between $5 and $7, not too high.
$Esperion Therapeutics (ESPR.US)$ i observed for years that 6 out of 10 persons are overweight or obese. For ESPR with a good med. that can help people to defend the obesity epidemic, how can its stock price keep falling?!
5
Report
Fortune Smiles 88
:
its not an obesity medicine. it is for lowering cholesterol and a substitute for statin drugs in the market now
DazzlerAus
70659822
OP
:
nope you can be thin with high cholesterol and you can be very fat wth low cholesterol you are at higher risk is your overweight but its a conplex link
$Esperion Therapeutics (ESPR.US)$以下为未经证实的消息,请自行判断。 $DSKNY #Daiichsankyo Is newly rumored to be ready to acquire $ESPR Esperion Therapeutics, before #Otsuka $OTSKY a partner of Esperion which is soon to start sales of it's healthy alternative to statin therapy drugs in Japan, Nexletol, Nexlizet label in U.S & Nilemdo, Nustendi
2
3
Report
DazzlerAus
:
interesting was that published or twitter?
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Esperion Therapeutics Stock Forum
Daiichi Sankyo Europe (DSE) Poised to Acquire Esperion Therapeutics Amid Leaked Insider Information
Recent rumors circulating on social media, supported by credible leaks from individuals connected to both DSE and E...
JMP 证券分析师 Roy Buchanan 重申了对 Esperion Therapeutics (NASDAQ:ESPR) 股票的 市场表现优于大盘 评级,并维持 7 美元的目标股价。
i observed for years that 6 out of 10 persons are overweight or obese. For ESPR with a good med. that can help people to defend the obesity epidemic, how can its stock price keep falling?!
No comment yet